Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AMS/PHARM stock hub

AMS/PHARM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AMS/PHARMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

779M

Euronext Amsterdam

Market data

Live price

Current market quote for this ticker.

Current price

AMS/PHARM

In the news

Latest news · AMS/PHARM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E40.4

P25 n/aP50 n/aP75 n/a

Trailing P/E78

P25 n/aP50 n/aP75 n/a

ROE5

P25 n/aP50 n/aP75 n/a

ROIC10

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AMS/PHARM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

218

Groups with data

Currency

USD

Showing 218 of 218 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Netherlands
Country code	NL
Employees	407
Employees Change	3%
Employees Change Percent	0.74
Enterprise value	EUR 732.2M
Exchange	Euronext Amsterdam
Financial currency	USD
First seen	2026-05-10
Industry	Biotechnology
Isin	NL0010391025
Last refreshed	2026-05-10
Market cap	EUR 779M
Price	EUR 1.1
Price currency	EUR
Rev Per Employee	787,361.36x
Sector	Healthcare
Sic	2836
Symbol	ams/PHARM
Website	https://www.pharming.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.38%
EV Earnings	68.32x
EV/EBIT	23.86x
EV/EBITDA	19.74x
EV/FCF	15.15x
EV/Sales	2.28x
FCF yield	6.2%
Forward P/E	40.44x
P/B ratio	3.34x
P/E ratio	77.96x
P/S ratio	2.43x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	9.44%
EBITDA Margin	11.44%
FCF margin	15.08%
Gross margin	88.14%
Gross Profit	EUR 282.5M
Gross Profit Growth	14.12%
Gross Profit Growth Q	-7.02%
Gross Profit Growth3 Y	20.79%
Gross Profit Growth5 Y	12.61%
Net Income	EUR 10.7M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Net Income Growth5 Y	-19.76%
Pretax Margin	5.38%
Profit Margin	3.34%
Profit Per Employee	EUR 26,332
Profitable Years	1
ROA	4.89
Roa5y	1.24
ROCE	9.25
ROE	5.04
Roe5y	1.21
ROIC	10
Roic5y	1.06

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	17.97%
Cagr15y	-2.19%
Cagr1y	44.6%
Cagr20y	-16.12%
Cagr3y	0.89%
Cagr5y	0.55%
EPS Growth Quarters	4
EPS Growth Years	1
EPS Growth5 Y	-22.02
FCF Growth	994.32%
FCF Growth5 Y	-2.9%
OCF Growth	827.48%
OCF Growth Q	741.38%
OCF Growth5 Y	-4.37%
Revenue Growth	15.21x
Revenue Growth Q	-8.4x
Revenue Growth Years	4x
Revenue Growth3 Y	22.39x
Revenue Growth5 Y	12.79x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.83
Assets	EUR 424.4M
Cash	EUR 147.6M
Current Assets	EUR 250.6M
Current Liabilities	EUR 95.3M
Debt	EUR 100.8M
Debt EBITDA	EUR 2.75
Debt Equity	EUR 0.43
Debt FCF	EUR 2.09
Equity	EUR 233.3M
Interest Coverage	3.25
Liabilities	EUR 191.2M
Long Term Assets	EUR 173.8M
Long Term Liabilities	EUR 95.9M
Net Cash	EUR 46.8M
Net Cash By Market Cap	EUR 6.01
Net Debt EBITDA	EUR -1.28
Net Debt Equity	EUR -0.2
Net Debt FCF	EUR -0.97
Tangible Book Value	EUR 119.7M
Tangible Book Value Per Share	EUR 0.16
WACC	5

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.63
Inventory Turnover	0.71
Net Working Capital	EUR 18.3M
Quick ratio	2.05
Working Capital	EUR 158.9M
Working Capital Turnover	EUR 2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-13.48%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	421.73%
1Y total return	44.56%
200-day SMA	1.33
3Y total return	2.7%
50-day SMA	1.4
50-day SMA vs 200-day SMA	50over200
5Y total return	2.8%
All Time High	306.7
All Time High Change	-99.64%
All Time High Date	2000-03-10
All Time Low	0.06
All Time Low Change	1,769.49%
All Time Low Date	2013-04-24
ATR	0.07
Beta	0.12
Beta1y	0.55
Beta2y	0.77
Ch YTD	-22.65
High	1.11
High52	1.82
High52 Date	2026-01-28
High52ch	-39.33%
Low	1.03
Low52	0.8
Low52 Date	2025-05-08
Low52ch	38.05%
Ma50ch	-20.99%
Price vs 200-day SMA	-17.19%
RSI	25.56
RSI Monthly	48.67
RSI Weekly	38.8
Sharpe ratio	0.63x
Sortino ratio	1.01
Total Return	-13.48%
Tr YTD	-22.65
Tr15y	-28.3%
Tr1m	-22.02%
Tr1w	-22.76%
Tr3m	-19.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 30.3M
Operating Income Growth	158.9
Operating Income Growth5 Y	-10.75
Operating margin	9.44

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	695,284,727%
Net Borrowing	-13,995,612.8
Shares Insiders	1.55%
Shares Institutions	22.84%
Shares Out	706,252,300
Shares Qo Q	-1.64%
Shares Yo Y	13.48%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 35.8M
Average Volume	13,952,260.2x
Bv Per Share	0.31
CAPEX	EUR -611,447
Ch10y	417.8
Ch15y	-28.84
Ch1m	-22.05
Ch1w	-22.76
Ch1y	44.56
Ch20y	-97.05
Ch3m	-19.25
Ch3y	2.7
Ch5y	2.8
Ch6m	-20.93
Change	6.52%
Change From Open	6.06
Close	1.04
Days Gap	0.39
Depreciation Amortization	6,268,983.1
Dollar Volume	33,476,155.9
Earnings Date	2026-05-07
EBIT	EUR 30.3M
EBITDA	EUR 36.7M
EPS	EUR 0.01
F Score	5
FCF	EUR 48.3M
FCF EV Yield	6.6x
FCF Per Share	EUR 0.07
Financing CF	-874,238
Fiscal Year End	December
Founded	1,988
Graham Number	0.31578
Graham Upside	-71.37
Income Tax	EUR 6.7M
Investing CF	-59,148,993
Is Primary Listing	1
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2013-03-05
Last Split Type	Reverse
Lynch Fair Value	EUR 0.07
Lynch Upside	-93.59
Ma150	1.4
Ma150ch	-21.16%
Ma20	1.41
Ma20ch	-21.99%
Net CF	-6,690,352
Next Earnings Date	2026-07-30
Open	1.04
P FCF Ratio	16.12
P OCF Ratio	15.92
Position In Range	93.75
Ppne	19,586,226.3
Price Date	2026-05-08
Price EBITDA	EUR 21.24
Ptbv Ratio	6.51
Relative Volume	2.29x
Revenue	320,456,075x
SBC By Revenue	3.9x
Share Based Comp	12,502,130
Tax By Revenue	2.08x
Tax Rate	38.57%
Tr20y	-97.03%
Tr6m	-20.93%
Volume	30,350,096

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AMS/PHARM pay a dividend?

Capital-return profile for this ticker.

Performance

AMS/PHARM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AMS/PHARM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+22.8%

Share of float held by funds and institutions

Insider ownership

+1.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+13.5%

Negative means the company is buying back shares.

Technical

AMS/PHARM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

25.6

Below 30: short-term oversold

Price vs 200-day MA

-17.2%

50/200-day relationship not available

Beta (5Y)

0.12

Less volatile than the market

Sharpe ratio

0.63

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AMS/PHARM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ams/PHARM stock rating?

ams/PHARM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ams/PHARM analysis?

The full report lives at /stocks/ams/PHARM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ams/PHARM?

The latest report frames ams/PHARM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ams/PHARM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.